US › Healthcare

Xilio Development Inc (XLO)

US · Healthcare · Biotechnology

$8.55-5.21%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$18.7M

Revenue YoY

+131.2%

Net profit

$-6.4M

EPS

$-0.33

EPS estimate

$-0.59

Net margin

-34.1%

EPS came in at -0.33 against a street estimate of -0.59 — a beat of 44.1%.

Key statistics

Market cap

$59.6M

Forward P/E

0.0

P/B

0.81

Book value

$10.98

EPS (TTM)

$-0.60

52-week high

$12.59

52-week low

$6.47

50-day MA

$9.07

200-day MA

$8.57

Beta

-0.12

Analyst view

Analysts rate Xilio Development Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $20.00.

Shareholding

Insiders

25.98%

Institutions

50.16%

Largest institutional holders

Fund	Stake
Bain Capital Life Sciences Investors, LLC	10.09%
Orbimed Advisors LLC	9.00%
Frazier Life Sciences Management, L.P.	6.42%
Stonepine Capital Management Llc	3.43%
Vanguard Capital Management, LLC	2.71%
Sio Capital Management, LLC	2.32%
Adage Capital Partners Gp LLC	1.70%
Merck & Co Inc	1.61%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Xilio Development Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.